Sequelae of; Infection
6
0
0
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
17%
1 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19
Assessment of Long-term Sequelae of Coronavirus Disease 2019 (COVID-19) Pneumonia With Chest CT and Pulmonary Function Tests
mNGS for Therapy of Urinary Infectious Diseases
COVID-Like Illness Respiratory Pathogens. A Prospective Cohort on the COVID-19 Post-acute Condition
COVID-19: A Scope Research on Epidemiology and Clinical Course
Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2